289 related articles for article (PubMed ID: 12115353)
1. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma.
Arrieta O; Garcia E; Guevara P; Garcia-Navarrete R; Ondarza R; Rembao D; Sotelo J
Cancer; 2002 Jun; 94(12):3210-8. PubMed ID: 12115353
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor (HGF) and receptor (c-met) in normal and malignant astrocytic cells.
Welch WC; Kornblith PL; Michalopoulos GK; Petersen BE; Beedle A; Gollin SM; Goldfarb RH
Anticancer Res; 1999; 19(3A):1635-40. PubMed ID: 10470094
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas.
MartÃnez-Rumayor A; Arrieta O; Guevara P; Escobar E; Rembao D; Salina C; Sotelo J
Cancer Lett; 2004 Sep; 213(1):117-24. PubMed ID: 15312691
[TBL] [Abstract][Full Text] [Related]
4. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
5. Microvessel density in brain tumors.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Papadakis N; Varakis I
Anticancer Res; 1997; 17(6D):4747-53. PubMed ID: 9494601
[TBL] [Abstract][Full Text] [Related]
6. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer.
Yamashita J; Ogawa M; Yamashita S; Nomura K; Kuramoto M; Saishoji T; Shin S
Cancer Res; 1994 Apr; 54(7):1630-3. PubMed ID: 8137271
[TBL] [Abstract][Full Text] [Related]
7. Multiparameter flow cytometric analysis of neoplasms of the central nervous system: correlation of nuclear antigen p105 and DNA content with clinical behavior.
Appley AJ; Fitzgibbons PL; Chandrasoma PT; Hinton DR; Apuzzo ML
Neurosurgery; 1990 Jul; 27(1):83-96. PubMed ID: 2377285
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4.
Brockmann MA; Papadimitriou A; Brandt M; Fillbrandt R; Westphal M; Lamszus K
Clin Cancer Res; 2003 Oct; 9(12):4578-85. PubMed ID: 14555533
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan.
Chen YS; Wang JT; Chang YF; Liu BY; Wang YP; Sun A; Chiang CP
J Oral Pathol Med; 2004 Apr; 33(4):209-17. PubMed ID: 15061708
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
11. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of tissue endostatin in human malignant gliomas.
Morimoto T; Aoyagi M; Tamaki M; Yoshino Y; Hori H; Duan L; Yano T; Shibata M; Ohno K; Hirakawa K; Yamaguchi N
Clin Cancer Res; 2002 Sep; 8(9):2933-8. PubMed ID: 12231538
[TBL] [Abstract][Full Text] [Related]
13. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor.
Guerin C; Luddy C; Abounader R; Lal B; Laterra J
Biochem Biophys Res Commun; 2000 Jun; 273(1):287-93. PubMed ID: 10873600
[TBL] [Abstract][Full Text] [Related]
14. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
15. [mRNA expression of basic fibroblast growth factor and hepatocyte growth factor in gastric carcinoma and significance thereof].
Ru GQ; Zhao ZS; Tang QL; Xu WJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2030-5. PubMed ID: 19080429
[TBL] [Abstract][Full Text] [Related]
16. Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma.
Vejchapipat P; Tangkijvanich P; Theamboonlers A; Chongsrisawat V; Chittmittrapap S; Poovorawan Y
J Gastroenterol; 2004 Dec; 39(12):1182-8. PubMed ID: 15622483
[TBL] [Abstract][Full Text] [Related]
17. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema.
Oh J; Cha S; Aiken AH; Han ET; Crane JC; Stainsby JA; Wright GA; Dillon WP; Nelson SJ
J Magn Reson Imaging; 2005 Jun; 21(6):701-8. PubMed ID: 15906339
[TBL] [Abstract][Full Text] [Related]
18. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
19. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
20. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
Chau GY; Lui WY; Chi CW; Chau YP; Li AF; Kao HL; Wu CW
Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
